The invention relates to new purine derivatives of general formula
1
wherein R
1
to R
4
are defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.
                            本发明涉及通式如下的新
嘌呤衍
生物
1
其中 R
1
至 R
4
的同系物、立体异构体、混合物、原药及其盐,特别是其与
无机酸或有机酸或碱的生理上可接受的盐,这些盐具有重要的药理特性,特别是对二肽基肽酶-IV (
DPP-IV)酶活性的抑制作用,其制备方法、将其用于预防或治疗与 
DPP-IV 活性增强相关的疾病或病症,或通过降低 
DPP-IV 活性而预防或缓解的疾病或病症,特别是 I 型或 II 型糖尿病;含有通式(I)化合物或其生理上可接受的盐的药物组合物及其制备工艺。